

Company Name: EIKEN CHEMICAL Co., Ltd.
 Representative: Morifumi Wada, President & CEO
 Securities code: 4549 (TSE 1st Section)

Revision of the Financial Forecast for the first six months of fiscal year ending March 31, 2018

In light of recent trends in its business performance, Eiken Chemical Co., Ltd. has been revised that the consolidated financial forecast for first six months of the fiscal year ending in March 31, 2018, which was released on April 27, 2017.

Revision of consolidated financial forecast for the first six months of fiscal year ending March 31, 2018
 (April 1 to September 30, 2017)

	Net sales	Operating income	Ordinary income	Net income attributable to shareholders of parent company	Net income per share
	million yen	million yen	million yen	million yen	Yen
Previous forecast (A)	18,000	1,400	1,400	1,000	54.60
Revised forecast (B)	17,630	2,280	2,310	1,680	91.71
Change (B-A)	(370)	880	910	680	
Change ratio (%)	(2.1)	62.9	65.0	68.0	
Reference: Actual results for the previous fiscal year (first six months of fiscal year ended March 31, 2017)	16,804	2,325	2,343	1,715	93.68

Revision of non-consolidated financial forecast for the first six months of fiscal year ending March 31, 2018 (April 1 to September 30, 2017)

	Net sales	Operating income	Ordinary income	Net income	Net income per share
	million yen	million yen	million yen	million yen	Yen
Previous forecast (A)	17,920	1,450	1,450	1,050	57.33
Revised forecast (B)	17,600	2,320	2,340	1,700	92.80
Change (B-A)	△320	870	890	650	
Change ratio (%)	△1.8	60.0	61.4	61.9	
Reference: Actual results for the previous fiscal year (first six months of fiscal year ended March 31, 2017)	16,795	2,352	2,366	1,738	94.69

Reason for Revision

(1) Sales

Regarding overseas sales, although it is expected to increase compared to the previous fiscal year, it is expected to be lower than initially forecast due to sluggish sales of fecal immunochemical test reagents and LAMP reagent sales. Regarding domestic sales, it is expected as originally anticipated.

(2) Profit

Profit will significantly increase due to that the development cost-about 750 million yen- of the compact fully automated genetic testing device scheduled in this second quarter consolidated accounting period will be carried over to the fourth quarter, and also the cost reduction by efficient use.

For both sales and profit, there is no change in the forecast for full year of the fiscal year ending March 31, 2018.

Note: Forecast in this disclosure is made by management in light of information currently available. A number of factors could cause actual results to differ materially from those disclosed as above.